4.7 Article

Ultrasensitive visual detection of miRNA-143 using a CRISPR/Cas12a-based platform coupled with hyperbranched rolling circle amplification

期刊

TALANTA
卷 251, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.talanta.2022.123784

关键词

MicroRNA; CRISPR; Cas12a; Hyperbranched rolling circle amplification; Colorimetric detection

向作者/读者索取更多资源

This study developed a new detection method based on gold nanoparticles and CRISPR/Cas12a for highly sensitive detection of miRNA-143 as a noninvasive biomarker for prostate cancer diagnosis. The method exhibited outstanding specificity and sensitivity, and it is simple to operate, making it suitable for use in low-resource settings.
MicroRNAs are proposed novel biomarker for noninvasive diagnosis of cancer. miRNA-143 is reported to be associated with the development of prostate cancer. However, detection of miRNAs is still challenging due to their unique characteristics, such as small size and high sequence homology among family members. We here developed a gold nanoparticle (AuNP)-based visual assay that combines with CRISPR/Cas12a-assisted hyper -branched rolling circle amplification (HRCA), which is called HRCA enhanced CRISPR/Cas12a-based assay (HECA) for sensitive detection of miRNA-143. The sequence-specific recognition character of CRISPR/Cas12a and HRCA signal amplification strategy enables the HECA outstanding specificity and sensitivity. In optimal condition, 1 fM miRNA-143 could be detected by naked eyes, and down to aM level with the aid of UV-Vis instrument. The diagnostic performance of the HECA for clinical samples was also evaluated based on the receiving operating characteristic algorithm (ROC), and our results suggest the miR-143 is a promising biomarker for noninvasive diagnosis of prostate cancer. This method is simple in operation and requires mini-mum instrument. We expect it to be widely applied in clinical diagnostics, especially in low-resource settings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据